Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials
Authors:
Open Access
- 1 October 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (2) , 335-342
Abstract
Objective. Although the incidence of dcSSc is higher in African-American and Hispanic populations compared with European Caucasian patients, it is not clear whether there are differences in subsequent disease course. Also, the potential impact of gender on the disease course of dcSSc is not well defined. Our objective was to assess the course of modified Rodnan skin score (MRSS), HAQ-disability index (HAQ-DI) and forced vital capacity per cent (FVC%) predicted between men vs women and three ethnic groups with dcSSc participating in three randomized clinical trials (RCTs). Method. Data from RCTs (n = 495) were pooled and analysed. Baseline characteristics were compared in men vs women and among ethnic groups. A linear mixed effects model was used to assess the predictors of MRSS, HAQ-DI and FVC%. The primary independent variables were time-in-study and its interaction with gender and ethnicity. The models were adjusted for other covariates that were significant at baseline between gender and ethnicity analyses. Results. Men had lower HAQI-DI scores compared with women (P < 0.05). Among the three ethnic groups, Caucasians were older, African-Americans had lower FVC% predicted and Hispanics had greater tender joint counts (P < 0.05). The course of MRSS, HAQ-DI and FVC% predicted during the study period was not significantly different between gender and three ethnicities. Time-in-study was an independent predictor of improvement in MRSS and HAQ-DI. Conclusion. Our analysis explores the influence of gender and ethnicity on disease course in RCTs. These findings are relevant to issues of future trial design.Keywords
This publication has 20 references indexed in Scilit:
- Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trialRheumatology, 2010
- Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double‐blind, randomized controlled trialsArthritis & Rheumatism, 2009
- Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2009
- A multicenter, randomized, double‐blind, placebo‐controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late‐phase diseaseArthritis & Rheumatism, 2008
- Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factorsArthritis Care & Research, 2007
- Systemic Sclerosis Mortality in the United States: 1979–1998European Journal of Epidemiology, 2005
- Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US populationArthritis & Rheumatism, 2003
- Correlates of the disability index of the health assessment questionnaire: A measure of functional impairment in systemic sclerosisArthritis & Rheumatism, 1999
- Racial differences in scleroderma among women in MichiganArthritis & Rheumatism, 1997
- Severe restrictive lung disease in systemic sclerosisArthritis & Rheumatism, 1994